Digoxin Drug-Drug Interaction With Lurasidone HCl

Sumitomo Pharma America, Inc.24 enrolled

Overview

The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.

Study Type

INTERVENTIONAL

Allocation

Enrollment

Conditions

Schizophrenia

Interventions

LurasidoneDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female 18 to 65 years of age * BMI \>= 19.5 and \<= 37 kg/m2 * No clinically relevant abnormal laboratory values Exclusion Criteria: * History or presence of renal or hepatic insufficiency * Participated in a clinical trial in the past 30 days * Use of con meds that prolong the QT/QTc taken within 28 days prior to study drug administration

Locations (1)

California Clinical Trials

Culver City, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.